1. Home
  2. Live Updates
  3. Transcenta Debuts Encouraging Phase II Data from First-line

Transcenta Debuts Encouraging Phase II Data from First-line

Transcenta Debuts Encouraging Phase II Data from First-line Triple Combo Trial of Osemitamab for G/GEJ Cancer at ASCO 2024

BioPharma

Related Keywords

China , Suzhou , Jiangsu , , Transcenta Holding Limited , Holding Limited , Clinical Oncology Volume ,

© 2025 Vimarsana